propiomazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2298 | 362-29-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 25 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.45 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 33 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 5, 1960 | FDA | HIKMA MAPLE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05CM06 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Other hypnotics and sedatives |
| CHEBI has role | CHEBI:37930 | phenothiazine antipsychotic drug |
| CHEBI has role | CHEBI:48561 | dopaminergic antagonist |
| CHEBI has role | CHEBI:48279 | serotonergic antagonist |
| CHEBI has role | CHEBI:48876 | muscarinic antagonist |
| CHEBI has role | CHEBI:37956 | histamine antagonist |
| CHEBI has role | CHEBI:35717 | sedative |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| General anesthesia | indication | 50697003 | |
| Local anesthesia | indication | 386761002 | |
| Alcoholism | contraindication | 7200002 | |
| Organophosphate poisoning | contraindication | 8260003 | |
| Weight gain finding | contraindication | 8943002 | |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Senile dementia | contraindication | 15662003 | |
| Chronic disease of respiratory system | contraindication | 17097001 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Orthostatic hypotension | contraindication | 28651003 | |
| Torsades de pointes | contraindication | 31722008 | |
| Parkinsonism | contraindication | 32798002 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Extrapyramidal disease | contraindication | 76349003 | |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Stupor | contraindication | 89458003 | |
| Tardive dyskinesia | contraindication | 102449007 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Acute disease of cardiovascular system | contraindication | 128487001 | |
| Angina pectoris | contraindication | 194828000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Metabolic syndrome X | contraindication | 237602007 | DOID:14221 |
| Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Coma | contraindication | 371632003 | |
| At risk for aspiration | contraindication | 371736008 | |
| Visual impairment | contraindication | 397540003 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Carcinoma of female breast | contraindication | 447782002 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.19 | Basic |
| pKa2 | 1.58 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H1 receptor | GPCR | ANTAGONIST | WOMBAT-PK | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | WOMBAT-PK | |||||||
| D(4) dopamine receptor | GPCR | WOMBAT-PK | |||||||
| Muscarinic acetylcholine receptor M5 | GPCR | WOMBAT-PK | |||||||
| Muscarinic acetylcholine receptor M4 | GPCR | WOMBAT-PK | |||||||
| Muscarinic acetylcholine receptor M3 | GPCR | WOMBAT-PK | |||||||
| Muscarinic acetylcholine receptor M2 | GPCR | WOMBAT-PK | |||||||
| Muscarinic acetylcholine receptor M1 | GPCR | WOMBAT-PK | |||||||
| 5-hydroxytryptamine receptor 2C | GPCR | WOMBAT-PK | |||||||
| 5-hydroxytryptamine receptor 2A | GPCR | WOMBAT-PK | |||||||
| D(2) dopamine receptor | GPCR | WOMBAT-PK | |||||||
| D(1A) dopamine receptor | GPCR | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019914 | VUID |
| N0000147999 | NUI |
| C0033473 | UMLSCUI |
| D02361 | KEGG_DRUG |
| 242Z0PM79Y | UNII |
| 735 | INN_ID |
| 1240-15-9 | SECONDARY_CAS_RN |
| 41324009 | SNOMEDCT_US |
| 4019914 | VANDF |
| d00914 | MMSL |
| 8770 | RXNORM |
| 373493007 | SNOMEDCT_US |
| 001488 | NDDF |
| CHEMBL252103 | ChEMBL_ID |
| C084591 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB00777 | DRUGBANK_ID |
| CHEBI:8491 | CHEBI |
| CHEMBL1201068 | ChEMBL_ID |
| CHEMBL1201210 | ChEMBL_ID |
| 4940 | PUBCHEM_CID |
| 7284 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
None